Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
<h4>Introduction</h4>Methods used for epidermal growth factor receptor (EGFR) mutation testing vary widely. The impact of detection methods on the rates of response to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-wild type (wt) lung adenocarcinoma patients is unknown.<h4>Methods&...
Guardado en:
Autores principales: | Jeng-Sen Tseng, Chih-Liang Wang, Ming-Shyan Huang, Chung-Yu Chen, Cheng-Yu Chang, Tsung-Ying Yang, Chi-Ren Tsai, Kun-Chieh Chen, Kuo-Hsuan Hsu, Meen-Hsin Tsai, Sung-Liang Yu, Kang-Yi Su, Chih-Wei Wu, Cheng-Ta Yang, Yuh-Min Chen, Gee-Chen Chang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f321764dc4834253830724de3df3add0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Yen-Hsiang Huang, et al.
Publicado: (2021) -
Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Yen-Hsiang Huang, et al.
Publicado: (2021) -
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
por: Shang-Gin Wu, et al.
Publicado: (2011) -
Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation
por: Yu-Mu Chen, et al.
Publicado: (2021) -
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
por: Florent Baty, et al.
Publicado: (2013)